Cargando…
Antiviral drugs specific for coronaviruses in preclinical development
Coronaviruses are positive stranded RNA viruses that cause respiratory, enteric and central nervous system diseases in many species, including humans. Until recently, the relatively low burden of disease in humans caused by few of these viruses impeded the development of coronavirus specific therape...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4195804/ https://www.ncbi.nlm.nih.gov/pubmed/24997250 http://dx.doi.org/10.1016/j.coviro.2014.06.002 |
_version_ | 1782339362607857664 |
---|---|
author | Adedeji, Adeyemi O Sarafianos, Stefan G |
author_facet | Adedeji, Adeyemi O Sarafianos, Stefan G |
author_sort | Adedeji, Adeyemi O |
collection | PubMed |
description | Coronaviruses are positive stranded RNA viruses that cause respiratory, enteric and central nervous system diseases in many species, including humans. Until recently, the relatively low burden of disease in humans caused by few of these viruses impeded the development of coronavirus specific therapeutics. However, the emergence of severe acute respiratory syndrome coronavirus (SARS-CoV), and more recently, Middle East respiratory syndrome coronavirus (MERS-CoV), has impelled the development of such drugs. This review focuses on some newly identified SARS-CoV inhibitors, with known mechanisms of action and their potential to inhibit the novel MERS-CoV. The clinical development of optimized versions of such compounds could be beneficial for the treatment and control of SARS-CoV, the current MERS-CoV and other future SARS-like epidemics. |
format | Online Article Text |
id | pubmed-4195804 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-41958042015-10-01 Antiviral drugs specific for coronaviruses in preclinical development Adedeji, Adeyemi O Sarafianos, Stefan G Curr Opin Virol Article Coronaviruses are positive stranded RNA viruses that cause respiratory, enteric and central nervous system diseases in many species, including humans. Until recently, the relatively low burden of disease in humans caused by few of these viruses impeded the development of coronavirus specific therapeutics. However, the emergence of severe acute respiratory syndrome coronavirus (SARS-CoV), and more recently, Middle East respiratory syndrome coronavirus (MERS-CoV), has impelled the development of such drugs. This review focuses on some newly identified SARS-CoV inhibitors, with known mechanisms of action and their potential to inhibit the novel MERS-CoV. The clinical development of optimized versions of such compounds could be beneficial for the treatment and control of SARS-CoV, the current MERS-CoV and other future SARS-like epidemics. Elsevier B.V. 2014-10 2014-07-02 /pmc/articles/PMC4195804/ /pubmed/24997250 http://dx.doi.org/10.1016/j.coviro.2014.06.002 Text en Copyright © 2014 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Adedeji, Adeyemi O Sarafianos, Stefan G Antiviral drugs specific for coronaviruses in preclinical development |
title | Antiviral drugs specific for coronaviruses in preclinical development |
title_full | Antiviral drugs specific for coronaviruses in preclinical development |
title_fullStr | Antiviral drugs specific for coronaviruses in preclinical development |
title_full_unstemmed | Antiviral drugs specific for coronaviruses in preclinical development |
title_short | Antiviral drugs specific for coronaviruses in preclinical development |
title_sort | antiviral drugs specific for coronaviruses in preclinical development |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4195804/ https://www.ncbi.nlm.nih.gov/pubmed/24997250 http://dx.doi.org/10.1016/j.coviro.2014.06.002 |
work_keys_str_mv | AT adedejiadeyemio antiviraldrugsspecificforcoronavirusesinpreclinicaldevelopment AT sarafianosstefang antiviraldrugsspecificforcoronavirusesinpreclinicaldevelopment |